Form 4: Immunovant Director Jake Bauer Acquires Shares

Immunovant, Inc. Director Jake Bauer reported the acquisition of 13,880 shares of common stock and 7,061 stock options on April 7, 2026.

Summary

• Director Jake Bauer acquired 13,880 shares of Immunovant, Inc. common stock on April 7, 2026.
• The acquisition of common stock was valued at $0, indicating it was likely a grant or award.
• Bauer also acquired 7,061 stock options with an exercise price of $24.61, also on April 7, 2026.
• These stock options have an expiration date of April 7, 2036.
• The filing indicates that the common stock acquired represents restricted stock units (RSUs) granted under the Issuer's 2019 Equity Incentive Plan.
• These RSUs are set to vest in full on April 1, 2027, contingent on Bauer's continued service.
• The stock options were also granted under the same plan and are scheduled to vest on April 1, 2027, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It represents a routine grant of equity awards to a director, which is standard practice, rather than a significant new investment or divestment by an insider.

Positives

• Director Jake Bauer has increased his beneficial ownership in Immunovant, Inc. through the acquisition of common stock and stock options.
• The acquisition of stock options with a strike price of $24.61 suggests a belief in future stock price appreciation.
• The RSUs and options are scheduled to vest, aligning the director's interests with long-term company performance.

Negatives

• The acquisition of common stock was at a price of $0, suggesting these were granted rather than purchased on the open market, which may not represent new capital investment by the director.
• The vesting date for both RSUs and stock options is April 1, 2027, meaning the director's full benefit is contingent on continued employment until that date.

Risks

• The vesting of RSUs and stock options is contingent on the Reporting Person's continuous service to the Issuer as of the vesting date (April 1, 2027).
• The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A, which could introduce complexities.
• The stock options have an exercise price of $24.61, meaning they will only be profitable if the stock price exceeds this level by April 7, 2036.

Future Outlook

The future outlook for the acquired RSUs and stock options is tied to the company's performance, as they are subject to vesting on April 1, 2027, and the stock options have an expiration date of April 7, 2036. The value of these awards will depend on Immunovant's stock price exceeding the exercise price of $24.61 for the options.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Immunovant, Inc., are standard disclosures for insider transactions. Such filings are closely watched by investors to gauge management's confidence in the company's prospects. The grant of equity awards to directors is a common practice across the biotechnology and pharmaceutical sectors to incentivize long-term performance and align executive interests with shareholders.

Stakeholder Impact

• Shareholders: The filing indicates continued alignment of director compensation with long-term company performance through equity awards.
• Employees: The equity incentive plan under which these awards were granted may also benefit other employees, fostering a culture of shared success.
• Management: Reinforces the standard practice of incentivizing key personnel through equity compensation.

Next Steps

• Director Jake Bauer's continued service to Immunovant, Inc. through April 1, 2027, to ensure vesting of RSUs and stock options.
• Monitoring Immunovant, Inc.'s stock performance to determine the profitability of the acquired stock options by their expiration date in 2036.

Key Dates

Keywords

Immunovant, IMVT, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Equity Incentive Plan, Director Compensation, Beneficial Ownership